Axe Compute Inc. AGPU

What this company does

Through a distributed network model, Axe Compute seeks to provide customers with access to graphics processing unit (“GPU”) compute capacity for artificial intelligence and other high-performance computing workloads, sourced primarily through infrastructure made available by the Aethir network. In connection with this strategic expansion, we adopted a digital asset treasury strategy focused on the Aethir token (“ATH”), the native utility token of the Aethir network, to support our participation in the Aethir ecosystem (“Treasury Strategy”). Axe Compute also continues to operate its Drug Discovery Services business, which we also refer to as our ‘legacy’ business (“Legacy Business”), which is designed to support the discovery and development of optimal cancer therapies. In the Legacy Business, the Company uses AI and its proprietary biobank of 150,000+ tumor samples, categorized by tumor type, to provide actionable insights about drug compounds to improve the drug discovery process and increase the probability of drug compound success. The Company also creates and develops tumor-specific 3D cell culture models mimicking the physiological environment of human tissue, enabling better-informed decision-making during drug development.

Written from the business description in Axe Compute Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.